Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue
Product sales	$ 633,496	$ 734,502
Laboratory services	8,690	16,105
Collaboration revenue	204,040	21,164
Total revenue	846,226	771,771
Operating expenses
Cost of products sold	342,832	424,950
Cost of services	168,553	100,233
Research and development	1,230,429	2,122,515
General and administrative	1,790,522	1,969,216
Sales and marketing	329,773	1,105,586
Total operating expenses	3,862,109	5,722,500
Operating loss	(3,015,883)	(4,950,729)
Other (expense)/income
Interest and other income	5,298	21
Interest expense	(57,846)	(29,844)
Foreign currency transaction gains	12,181	2,620
Change in fair value of derivative financial instruments	8,166	0
Total other expense	(32,201)	(27,203)
Loss before income taxes	(3,048,084)	(4,977,932)
Provision for income taxes	0	0
Net loss	(3,048,084)	(4,977,932)
Net loss available to common stockholders	$ (3,048,084)	$ (4,977,932)
Net loss per common share - basic and diluted	$ (0.75)	$ (4.77)
Weighted average shares outstanding - basic and diluted	4,055,715	1,043,178
Net loss	$ (3,048,084)	$ (4,977,932)
Other comprehensive loss - foreign currency translation	(12,579)	(3,757)
Comprehensive loss	$ (3,060,663)	$ (4,981,689)